Trial Profile

A Phase 3, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 22 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Guselkumab (Primary) ; Guselkumab (Primary)
Indications Crohn's disease
Focus Adverse reactions; Registrational
Sponsors Janssen Pharmaceutical KK

Most Recent Events

12 Sep 2023 Status changed from recruiting to active, no longer recruiting.
03 Nov 2022 Planned primary completion date changed from 30 Sep 2024 to 1 Mar 2024.
11 Aug 2022 Planned End Date changed from 28 Feb 2025 to 1 Jun 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com